A Randomized, Double-blinded, Phase II, Placebo-controlled Study to Evaluate the Safety and Efficacy of SCT650C in Participants With Axial Spondyloarthritis
Latest Information Update: 11 Jan 2024
At a glance
- Drugs SCT 650C (Primary)
- Indications Axial spondyloarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 11 Jan 2024 New trial record